share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Patel Naimish

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Patel Naimish

CRISPR Therapeutics | 4：持股變動聲明-高管 Patel Naimish
美股sec公告 ·  05/30 04:20
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG's Chief Medical Officer, Patel Naimish, was involved in a transaction with the company's stock on May 28, 2024. However, the details of the transaction, including the action type, status, number of shares, nature of shares, transaction price, and total value of shares, have not been disclosed. The number of shares held by Patel Naimish after the transaction is also undisclosed. Investors are advised to await further information for a complete understanding of the transaction's impact on their investment decisions.
CRISPR Therapeutics AG's Chief Medical Officer, Patel Naimish, was involved in a transaction with the company's stock on May 28, 2024. However, the details of the transaction, including the action type, status, number of shares, nature of shares, transaction price, and total value of shares, have not been disclosed. The number of shares held by Patel Naimish after the transaction is also undisclosed. Investors are advised to await further information for a complete understanding of the transaction's impact on their investment decisions.
2024年5月28日，CRISPR Therapeutics AG的首席醫療官帕特爾·奈米什參與了與該公司股票的交易。但是，該交易的細節，包括行動類型、狀態、股票數量、股票性質、交易價格和股票總價值，尚未披露。交易後帕特爾·奈米什持有的股票數量也未公開。建議投資者等待進一步的信息，以全面了解該交易對其投資決策的影響。
2024年5月28日，CRISPR Therapeutics AG的首席醫療官帕特爾·奈米什參與了與該公司股票的交易。但是，該交易的細節，包括行動類型、狀態、股票數量、股票性質、交易價格和股票總價值，尚未披露。交易後帕特爾·奈米什持有的股票數量也未公開。建議投資者等待進一步的信息，以全面了解該交易對其投資決策的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。